Physicians Postgraduate Press, Inc. Unable to load your delegates due to an error 2009 Nov 26;2:9094. doi: 10.1186/1757-1626-2-9094.Sung VW, West DS, Hernandez AL, Wheeler TL 2nd, Myers DL, Subak LL; Program to Reduce Incontinence by Diet and Exercise (PRIDE).Am J Obstet Gynecol. In Summary.
Duloxetine, a dual-reuptake inhibitor of serotonin and norepinephrine, has been approved for the treatment of major depressive episodes and for female stress urinary incontinence.
7: Obstetrics, Gynaecology and Urinary Tract Disorders. Unable to load your collection due to an error Since the mechanism of action of duloxetine in the treatment of SUI is believed to be related to enhanced urethral closure forces, it is important to clarify the risk of acute urinary retention. Free PMC article
DULOXETINE, A SEROTONIN and norepinephrine reuptake inhibitor, has recently been approved for treatment of stress urinary incontinence in Europe. doi: 10.1016/j.ajog.2008.11.008. Unable to load your delegates due to an error Duloxetine was prescribed at a dosage of 20 mg a day and patient was advised to follow up in two weeks.
Overall, in the duloxetine placebo-controlled clinical studies in the treatment of MDD and SUI, obstructive voiding symptoms (reported either as subjective urinary retention or other obstructive voiding symptoms) occurred more often in patients receiving duloxetine (1.0%, 20/2097) than in patients receiving placebo (0.4%, 6/1732) (p <.05).
This case report demonstrates for the first time the onset of urinary retention in postpsychotic depression and during combined treatment with duloxetine and olanzapine. METHOD: The relationship between duloxetine and obstructive voiding symptoms was examined in 8 double-blind, 8- to 9-week, placebo-controlled studies and 1 open-label study in men and women treated for MDD with duloxetine 40 to 120 mg/day and in 4 double-blind, 12-week, placebo-controlled studies and 4 ongoing open-label studies in women treated for SUI with duloxetine 80 mg/day. If you experience any other symptoms which you think may be due to the capsules, please speak with your doctor or pharmacist for further advice. “Duloxetine Induced Urinary Retention: A Case Report”. RESULTS: In 378 men and 761 women with MDD treated in placebo-controlled trials, 0.4% (4/1139; 3 men and 1 woman) of those treated with active medication reported subjective urinary retention versus none (0/777) of those treated with placebo (p =.15). COVID-19 is an emerging, rapidly evolving situation. Some reports may have incomplete information.Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. Name must be less than 100 characters 2014 Aug;34(4):495-8. doi: 10.1097/JCP.0000000000000167.Pharmacopsychiatry.
2007 Aug;100(2):337-45. doi: 10.1111/j.1464-410X.2007.06980.x. Epub 2007 May 19.Prim Care Companion J Clin Psychiatry.